is the largest (n=46) and longest study of its kind to date.
In the study, patients taking
COPAXONE® for six years experienced an improvement
in neuronal mitochodrial function, as quantified by an increase in neuronal NAA levels and evaluated by 1H- Magnetic Resonance Spectroscopy (1H-MRS). Decreased neuronal NAA levels are reflective of neuronal/axonal injury.